EtoposideCisplatinAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsAntineoplastic Agents, PhytogenicIfosfamideDrug Administration ScheduleCarcinoma, Small CellDoxorubicinLung NeoplasmsCarboplatinTopoisomerase II InhibitorsCombined Modality TherapyDrug Resistance, NeoplasmPlatinumVincristinePodophyllotoxinCyclophosphamideDNA Topoisomerases, Type IIBleomycinVinblastineTreatment OutcomePaclitaxelLeukopeniaApoptosisGerminomaInfusions, IntravenousOvarian NeoplasmsTesticular NeoplasmsSurvival AnalysisCell Line, TumorDisease-Free SurvivalTumor Cells, CulturedCamptothecinDose-Response Relationship, DrugDNA DamageNeoplasms, Germ Cell and EmbryonalDrug Screening Assays, AntitumorAmsacrineDeoxycytidineSurvival RateFluorouracilDrug SynergismNeutropeniaDNA AdductsCytarabineDrug EvaluationCarcinoma, Non-Small-Cell LungRemission InductionCell SurvivalVomitingTeniposideDrug ResistanceHematologic DiseasesThrombocytopeniaCarmustineHead and Neck NeoplasmsSalvage TherapyCarcinoma, Squamous CellNeoplasm StagingVindesineNucleic Acid Synthesis InhibitorsNauseaTaxoidsAdministration, OralTopoisomerase InhibitorsTransplantation, AutologousNeoplasmsNeoplasm Recurrence, LocalMitomycinMitoxantroneAdenocarcinomaMethotrexateTopoisomerase I InhibitorsDrug Resistance, MultipleGranulocyte Colony-Stimulating FactorEpirubicinTumor Suppressor Protein p53Hodgkin DiseaseMelphalanCaspasesDNA RepairP-GlycoproteinSmall Cell Lung CarcinomaLymphoma, Non-HodgkinAlopeciaStomach NeoplasmsRetroperitoneal NeoplasmsTime FactorsChemotherapy, AdjuvantMaximum Tolerated DoseCell CycleProto-Oncogene Proteins c-bcl-2Antineoplastic Agents, AlkylatingPrognosisOrganophosphorus CompoundsBone Marrow DiseasesTopotecanProcarbazineOxonic Acid